Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07141914 · ClinicalTrials.gov registry record
A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World
A clinical trial, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- 285,327
- Enrollment target
NCT07141914 is a clinical trial that has completed, run by Novo Nordisk A/S. The registered enrollment target is 285,327 participants.
The verdict
NCT07141914 has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- 285,327 participants
- Enrollment target
Study Summary
This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic Cardiovascular Disease (ASCVD), primary prevention). This is a retrospective cohort study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for participants in the US during January 1, 2016 - December 31, 2024.
Interventions
- OTHER No treatment given
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285,327 participants |
| Start Date | 2025-08-29 |
| Est. Completion | 2025-12-19 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07141914
The ClinicalTrials.gov registry entry for NCT07141914 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 285,327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No treatment given is the first listed.
NCT07141914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07141914 about?
NCT07141914 is a clinical study titled "A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World". This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic Cardiovascular Disease (ASCVD), primary prevention). This is a retrospecti...
What is the current status of trial NCT07141914?
This trial is currently completed. The enrollment target is 285,327 participants. The study started on 2025-08-29. Estimated completion is 2025-12-19.
What interventions are being tested in trial NCT07141914?
The interventions under investigation include: No treatment given (OTHER).
Who is sponsoring clinical trial NCT07141914?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.